Professor Martin Stockler

Professor of Oncology and Clinical Epidemiology
Medicine, Central Clinical School

Telephone +61 2 9562 5313
Fax +61 2 9565 1863

Website Related website

Map

Research interests

Improving quality of life, survival, prognostication, and doctor-patient communication for those affected by cancer, particularly genitourinary (prostate, testis, kidney, bladder), breast and lung. Clinical trials, meta-analaysis, evidence based medicine, biostatistics.

Selected grants

2013

  • Accelerating First-Line Chemotherapy to Improve Cure Rates for Advanced Germ Cell Tumours: An Australian-Led, International Randomised Trial; Grimison P, Toner G, Stockler M, Friedlander M, Thomson D, Gebski V, King M, Quinn D, Singhal N; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.
  • Adding mitomycin C to intravesical BCG for high-risk, non-muscle-invasive bladder cancer: a randomised phase 3 trial; Hayne D, Patel M, Stockler M, Sengupta S, Frydenberg M, Chalasani V, Gebski V, Davis I; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.
  • Development and operational support for the Australasian Lung Cancer Trials Group (ALTG) through the NHMRC Clinical Trial Centre: A NSW-led initiative; Pavlakis N, Boyer M, Stockler M, Dhillon H, Links M, Brown C, Lewis C, Stubbin I; Cancer Institute New South Wales/Cooperative Clinical Trial (CCT) Grants.
  • Advancing the evidence base for care and policy in priority health areas; Simes R, Keech A, Gebski V, Stockler M, Caterson I, Colagiuri S, Schofield D, Marschner C; National Health and Medical Research Council (NHMRC)/Program Grants.
  • Development and operational support for ANZGOG through the NHMRC Clinical Trials Centre: A NSW lead initiative.; Brand A, Friedlander M, Stockler M, Sjoquist K, Gebski V; Cancer Institute New South Wales/Cooperative Clinical Trial (CCT) Grants.
  • Cancer Institute NSW Cooperative Clinical Trial Grant for ANZUP; Grimison P, Stockler M, Woo H, Patel M, Hayden A, Sandoe D; Cancer Institute New South Wales/Cooperative Clinical Trial (CCT) Grants.
  • A pharmacodynamic study of the heat shock protein 90 (Hsp90) inhibitor, AUY922, in high-risk, localised prostate cancer; Butler L, Horvath L, Tilley W, Stockler M, Stricker P, Kench J; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.

2012

  • PORTEC-3 - the role of adjuvant chemotherapy in high-risk endometrial cancer; Mileshkin L, Quinn M, Khaw P, Stockler M, Brand A, Martyn J, Sjoquist K, Creutzberg C; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.
  • Evaluation of a web-based tool for estimating and explaining prognosis in advanced cancer; Kiely B, Stockler M, Butow P, Tattersall M, Simes R; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.

2011

  • Using scenarios to estimate and explain survival time to people with incurable cancer; Kiely B, Stockler M; American Society of Clinical Oncology (USA)/Young Investigator Award.
  • START Trial: Phase III Study of Active Surveillance Therapy Against Radical Treatment in Patients Diagnosed with Favourable Risk Prostate Cancer; Millar J, Bolton D, Frydenberg M, Patel M, Williams S, Davis I, Stockler M; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.
  • NITRO: A Phase III, randomised trial of adding nitroglycerin to first line chemotherapy for advanced non-small cell lung cancer; Davidson A, Millward M, Boyer M, Millward M, Fong K, McLachlan S, Singhal N, Stockler M; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.

2009

  • Development and operational support for ALTG, ANZUP and GOGNO through the NHMRC Clinical Trials Centre: A NSW-led initiative; Stockler M, Simes R, Grimison P, Hague W; Cancer Institute New South Wales/Clinical Trials Infrastructure Grants.
  • Biostatistics, quality assurance and data systems for cancer trial groups activities based at the NHMRC Clinical Trials Centre; Gebski V, Simes R, Hague W, Gainford M, Stockler M, Goldstein D, Friedlander M, Grimison P; Cancer Institute New South Wales/Clinical Trials Infrastructure Grants.
  • Preferences for adjuvant chemotherapy in early non-small-cell lung cancer: What makes it worthwhile to patients and their doctors; McLachlan S, Duric V, Stockler M, Nowak A, Wright G, Boyer M, Hudson H; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.

2008

  • Australian and New Zealand Germ Cell Trials Group (ANZGCTG); Toner G, Stockler M; Cancer Australia/Support for Cancer Clinical Trials.
  • A randomised, phase III trial of adding nitroglycerin to first line chemotherapy in advanced non-small cell lung cancer; Davidson A, Boyer M, Stockler M; Cancer Council New South Wales/Research Project Grants.
  • Accelerated first line chemotherapy for advanced germ cell tumours; Friedlander M, Grimison P, Stockler M, Toner G; Cancer Council New South Wales/Research Project Grants.
  • Clinical trials advances for better health outcomes; Simes R, Keech A, Gebski V, Stockler M; National Health and Medical Research Council (NHMRC)/Project Grants.

2006

  • Strengthen Cancer Care initiative - Infrastructure Support for Clinical Trials Program (Psycho-Oncology Cooperative Research Group); Butow P, Mason C, King M, Solomon M, Stockler M, Tattersall M, Meiser B, Kelly B, White K, Meiser B, King M, Dunn S, Girgis A; Commonwealth Department of Health and Ageing/Strengthening Support For Cancer Care.
  • Nhmrc Clinical Trials Centre Clinical Trials Methodology And Practice Consultancy, Incorporating Utilisation And Enhancement Of A Web-Based Electronic Clinical Trials Data Management System And Repository; Simes R, Keech A, Gebski V, Hague W, Stockler M; National Health and Medical Research Council (NHMRC)/Enabling Grants.

2005

  • Sentinal node biopsy versus axillary clearence in breast cancer: the SNAC trial; Stockler M, Gebski V, Simes R; National Breast Cancer Foundation/Kathleen Cuningham Research Grant.
  • NSW psycho-oncology cooperative research group; Solomon M, Butow P, Stockler M, Dunn S, Meiser B, Tattersall M, White K, King M, Meiser B, Girgis A, Kelly B, Mason C, King M; Cancer Institute New South Wales/Research Grants Program - Category 3.
  • Infrastructure support for the AGITG and ANZGOG through the NHMRC Clinical Trials Centre - A NSW led initiative; Simes R, Stockler M; Cancer Institute New South Wales/Research Grant.

2004

  • A Phase II trial of gemcitabine in fixed dose rate infusion combined with cisplatin in patients with inoperable biliary tract carcinomas; Goldstein D, Conley R, Stockler M; Eli Lilly Australia Pty Limited/Research Support.
  • The Zest Trial : a double-blind, placebo-controlled trial of Zolofts effects on symptoms and survival time in advanced cancer; Stockler M, Byrne M, Nowak A, Wilken N, Turner J, Wyld D; Anti Cancer Foundation of South Australia/Research Support.
  • The Zest Trial : a double-blind, placebo-controlled trial of Zolofts effects on symptoms and survival time in advanced cancer; Stockler M, Byrne M, Nowak A, Wilken N, Turner J, Wyld D; Cancer Council New South Wales/Research Project Grants.
  • A randomised phase II study evaluating a weekly schedule of Docetaxel (Taxotere R) with cisplatin and 5-FU (wTCF) or with Capecitabine (Xeloda R) (wTX) in advanced oesophago-gastric cancer.; Conley R, Simes R, Stockler M; Aventis Pharma P/L & Aust Gastro Intestinal Trials Group/BLO Project.

2003

  • Sentinel node biopsy versus axillary clearance in early breast cancer: the SNAC Trial?; Gill P, Collins J, Wetzig N, Collins J, Ung O, Stockler M; National Health and Medical Research Council (NHMRC)/Clinical Trial Large Scale (CTLS).
  • Advances in clinical trials research and evidence-based decision making; Marschner C, Stockler M, Keech A, Simes R, Gebski V; National Health and Medical Research Council (NHMRC)/Program Grants.
  • Not known; Stockler M; University of Sydney/Cancer Research Fund.

2002

  • Patient preferences for adjuvant chemotherapy for early breast cancer: what makes it worthwhile?; Stockler M, Simes R, Coates A, Francis P, Reaby L; National Health and Medical Research Council (NHMRC)/Project Grants.

2001

  • Antidepressants and subjective well-being in advanced cancer: a double-blind randomised trial of Sertraline and St Johns Wort; Stockler M, Wilcken N, Simes R; Cancer Council New South Wales/Research Project Grants.
  • Antidepressants, well- being and survival in advanced cancer:The ZEST Trial.; Stockler M; Pfizer/BLO Project.

2000

  • Provision of assessment and research related services on medical technologies and procedures for the Medical Services Advisory Committee (MSAC); Simes R, Eckermann S, Keech A, Irwig L, Ghersi D, Stockler M, Gebski V, Eckermann S, Lord S, Howard K, Salkeld G; Department of Health and Ageing (Federal)/Research Support.

Selected publications

Download citations: PDF RTF Endnote

Books

  • Chapman, S., Barratt, A., Stockler, M. (2010). Let sleeping dogs lie What men should know before getting tested for prostate cancer. Sydney: Sydney University Press.

Book Chapters

  • Butow, P., Hagerty, R., Tattersall, M., Stockler, M. (2008). Foretelling: Communicating the prognosis. In N. Christakis and P. Glare (Eds.), Prognosis in Advanced Cancer, (pp. 33-53). Oxford: Oxford University Press.
  • Stockler, M., Duric, V., Coates, A. (2006). Patients' preferences: what makes treatments worthwhile? In Martine J. Piccart .. [et al.] (Eds.), Breast cancer and molecular medicine, (pp. 925-944). Berlin ; New York: Springer.

Journals

  • Grimison, P., Stockler, M., Chatfield, M., Thomson, D., Gebski, V., Friedlander, M., Boland, A., Houghton, B., Gruney, H., Rosenthal, M., et al (2014). Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Annals of Oncology, 25(1), 143-148. [More Information]
  • Lin, H., Castillo, L., Mahon, K., Chiam, K., Lee, B., Nguyen, Q., Boyer, M., Stockler, M., Pavlakis, N., Marx, G., Gurney, H., Horvath, L., et al (2014). Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. British Journal of Cancer, 110(10), 2462-2471. [More Information]
  • King, M., Stockler, M., Butow, P., O'Connell, R., Voysey, M., Oza, A., Gillies, K., Donovan, H., Mercieca-Bebber, R., Martyn, J., Sjoquist, K., Friedlander, M. (2014). Development of the measure of ovarian symptoms and treatment concerns: aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancer. International Journal of Gynecological Cancer, 24(5), 865-873. [More Information]
  • West, T., Kiely, B., Stockler, M. (2014). Estimating scenarios for survival time in men starting systemic therapies for castration-resistant prostate cancer: A systematic review of randomised trials. European Journal of Cancer, 50(11), 1916-1924. [More Information]
  • Stockler, M., Hilpert, F., Friedlander, M., King, M., Wenzel, L., Lee, C., Joly, F., de Gregorio, N., Arranz, J., Mirza, M., et al (2014). Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer. Journal of Clinical Oncology, 32(13), 1309-1316. [More Information]
  • Laurie, S., Solomon, B., Seymour, L., Ellis, P., Goss, G., Shepherd, F., Boyer, M., Arnold, A., Clingan, P., Laberge, F., Stockler, M., Lee, C., et al (2014). Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29. European Journal of Cancer, 50(4), 706-712. [More Information]
  • Karikios, D., Schofield, D., Salkeld, G., Mann, K., Trotman, J., Stockler, M. (2014). Rising cost of anticancer drugs in Australia. Internal Medicine Journal, 44(5), 458-463. [More Information]
  • Beumer, J., Gill, G., Campbell, I., Wetzig, N., Ung, O., Farshid, G., Uren, R., Stockler, M., Gebski, V. (2014). Sentinel node biopsy and large (≥3 cm) breast cancer. ANZ Journal of Surgery, 84(3), 117-120. [More Information]
  • Friedlander, M., Stockler, M., O'Connell, R., Voysey, M., Oza, A., Gillies, K., Donovan, H., Martyn, J., Sjoquist, K., Butow, P., King, M., et al (2014). Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit study. International Journal of Gynecological Cancer, 24(5), 857-864. [More Information]
  • Nowak, A., Brown, C., Millward, M., Creaney, J., Byrne, M., Hughes, B., Kremmidiotis, G., Bibby, D., Leske, A., Mitchell, P., Pavlakis, N., Stockler, M., et al (2013). A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. Lung Cancer, 81(3), 422-427. [More Information]
  • McCaughan, G., Blinman, P., Boyer, M., Stockler, M. (2013). Better estimates of survival for patients considering adjuvant chemotherapy after surgery for early non-small-cell lung cancer. Internal Medicine Journal, 43(4), 424-429. [More Information]
  • Gzell, C., Kench, J., Stockler, M., Hruby, G. (2013). Biopsy-proven brain metastases from prostate cancer: a series of four cases with review of the literature. International Urology and Nephrology, 45(3), 735-742. [More Information]
  • Friedlander, M., Stockler, M., Butow, P., King, M., McAlpine, J., Tinker, A., Ledermann, J. (2013). Clinical Trials of Palliative Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: Time to Think Differently? Journal of Clinical Oncology, 31(18), 2362. [More Information]
  • Blinman, P., Gainford, C., Donoghoe, M., Martyn, J., Bloomfield, P., Grant, P., Kichenadasse, G., Vaughan, M., Brand, A., Shannon, C., Gebski, V., Stockler, M., et al (2013). Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study. Journal of Gynecologic Oncology, 24(4), 359-366. [More Information]
  • Sjoquist, K., Friedlander, M., O'Connell, R., Voysey, M., King, M., Stockler, M., Oza, A., Gillies, K., Martyn, J., Butow, P. (2013). Hope, Quality of Life, and Benefit From Treatment in Women Having Chemotherapy for Platinum-Resistant/Refractory Recurrent Ovarian Cancer: The Gynecological Cancer Intergroup Symptom Benefit Study. The Oncologist, 18(11), 1221-1228. [More Information]
  • Stockler, M. (2013). Intermittent and continuous androgen deprivation did not differ for mortality after radiotherapy for prostate cancer. Annals of Internal Medicine, 158(2), JC9. [More Information]
  • Houghton, B., Chalasani, V., Hayne, D., Grimison, P., Brown, C., Patel, M., Davis, I., Stockler, M. (2013). Intravesical chemotherapy plus bacille Calmette-Guerin in non-muscle invasive bladder cancer: a systematic review with meta-analysis. BJU International, 111(6), 977-933. [More Information]
  • Coupe, N., Cox, K., Clark, K., Boyer, M., Stockler, M. (2013). Outcomes of Permanent Peritoneal Ports for the Management of Recurrent Malignant Ascites. Journal of Palliative Medicine, 16(8), 938-940. [More Information]
  • Grimison, P., Houghton, B., Chatfield, M., Toner, G., Davis, I., Martin, J., Hovey, E., Stockler, M. (2013). Patterns of management and surveillance imaging amongst medical oncologists in Australia for stage I testicular cancer. BJU International, 112(2), E35-E43. [More Information]
  • Price, M., Bell, M., Sommeijer, D., Friedlander, M., Stockler, M., deFazio, A., Webb, P., Butow, P. (2013). Physical symptoms, coping styles and quality of life in recurrent ovarian cancer: A prospective population-based study over the last year of life. Gynecologic Oncology, 130(1), 162-168. [More Information]
  • Olver, I., Grimison, P., Chatfield, M., Stockler, M., Toner, G., Gebski, V., Harrup, R., Underhill, C., Kichenadasse, G., Singhal, N., Boland, A., McDonald, A., et al (2013). Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy. Supportive Care in Cancer, 21(6), 1561-1568. [More Information]
  • Martin, A., Lord, S., Verry, H., Stockler, M., Emery, J. (2013). Risk assessment to guide prostate cancer screening decisions: a cost-effectiveness analysis. Medical Journal of Australia, 198(10), 546-550. [More Information]
  • Stark, D., Nankivell, M., Pujade-Lauraine, E., Kristensen, G., Elit, L., Stockler, M., Hilpert, F., Cervantes, A., Brown, J., Lanceley, A., et al (2013). Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncology, 14(3), 236-243. [More Information]
  • Thientosapol, E., Tran, T., Della-Fiorentina, S., Adams, D., Chantrill, L., Stockler, M., Kiely, B. (2013). Survival times of women with metastatic breast cancer starting first-line chemotherapy in routine clinical practice versus contemporary randomised trials. Internal Medicine Journal, 43(8), 883-888. [More Information]
  • Kiely, B., Martin, A., Tattersall, M., Nowak, A., Goldstein, D., Wilcken, N., Wyld, D., Abdi, E., Glasgow, A., Beale, P., Stockler, M., et al (2013). The Median Informs the Message: Accuracy of Individualized Scenarios for Survival Time Based on Oncologists' Estimates. Journal of Clinical Oncology, 31(28), 3565-3571. [More Information]
  • Smith, A., King, M., Butow, P., Luckett, T., Grimison, P., Toner, G., Stockler, M., Hovey, E., Stubbs, J., Hruby, G., Gurney, H., Turner, S., et al (2013). The prevalence and correlates of supportive care needs in testicular cancer survivors: a cross-sectional study. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer, 22(11), 2557-2564. [More Information]
  • Kiely, B., McCaughan, G., Christodoulou, S., Beale, P., Grimison, P., Trotman, J., Tattersall, M., Stockler, M. (2013). Using scenarios to explain life expectancy in advanced cancer: attitudes of people with a cancer experience. Supportive Care in Cancer, 21(2), 369-376. [More Information]
  • Wong, M., Stockler, M., Pavlakis, N. (2012). Bisphosphonates and other bone agents for breast cancer (Review). The Cochrane Library Chichester UK: John Wiley and Sons Ltd, 2, 1-136. [More Information]
  • Kiely, B., Alam, M., Blinman, P., Tattersall, M., Stockler, M. (2012). Estimating typical, best-case and worst-case life expectancy scenarios for patients starting chemotherapy for advanced non-small-cell lung cancer: A systematic review of contemporary randomized trials. Lung Cancer, 77(3), 537-544. [More Information]
  • Wilcken, N., Stockler, M. (2012). Individual patient meta-analysis: Taxane plus anthracycline reduces mortality from early breast cancer. Annals of Internal Medicine, 156(12), 432-444.
  • Kiely, B., Stockler, M. (2012). Meta-analysis: Adjuvant tamoxifen reduces recurrence and death at 15 years in ER-positive early breast cancer. Annals of Internal Medicine, 156(6), JC3-4-JC3-4. [More Information]
  • Blinman, P., King, M., Norman, R., Viney, R., Stockler, M. (2012). Preferences for cancer treatments: An overview of methods and applications in oncology. Annals of Oncology, 23(5), 1104-1110. [More Information]
  • King, M., Viney, R., Smith, D., Hossain, I., Street, D., Savage, E., Fowler, S., Berry, M., Stockler, M., Cozzi, P., Armstrong, B., et al (2012). Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer. British Journal of Cancer, 106(4), 638-645. [More Information]
  • Stockler, M., Wilcken, N. (2012). Why Is Management of Cancer Pain Still a Problem? Journal of Clinical Oncology, 30(16), 1907-1908. [More Information]
  • Lee, C., Hudson, M., Stockler, M., Coates, A., Ackland, S., Gebski, V., Lord, S., Friedlander, M., Boyle, F., Simes, R. (2011). A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer. Breast Cancer Research and Treatment, 129(2), 467-476. [More Information]
  • Stockler, M., Harvey, V., Francis, P., Byrne, M., Ackland, S., Fitzharris, B., Van Hazel, G., Wilcken, N., Grimison, P., Nowak, A., Zannino, D., Gebski, V., Coates, A., et al (2011). Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer. Journal of Clinical Oncology, 29(34), 4498-4504. [More Information]
  • Gennari, A., Stockler, M., Puntoni, M., Sormani, M., Nanni, O., Amadori, D., Wilcken, N., D'Amico, M., DeCensi, A., Bruzzi, P. (2011). Duration of Chemotherapy for Metastatic Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Journal of Clinical Oncology, 29(16), 2144-2149. [More Information]
  • Kiely, B., Soon, Y., Tattersall, M., Stockler, M. (2011). How Long Have I Got? Estimating Typical, Best-Case, and Worst-Case Scenarios for Patients Starting First-Line Chemotherapy for Metastatic Breast Cancer: A Systematic Review of Recent Randomized Trials. Journal of Clinical Oncology, 29(4), 456-463. [More Information]
  • Kiely, B., Wilcken, N., Stockler, M. (2011). Life after adjuvant chemotherapy for breast cancer: the news is mostly good. Journal of Clinical Oncology, 29(9), 1092-1093. [More Information]
  • Blinman, P., McLachlan, S., Nowak, A., Duric, V., Brown, C., Wright, G., Millward, M., Fong, K., Stockler, M. (2011). Lung cancer clinicians' preferences for adjuvant chemotherapy in non-small-cell lung cancer: What makes it worthwhile? Lung Cancer, 72(2), 213-218. [More Information]
  • Lyerly, H., Abernethy, A., Stockler, M., Koczwara, B., Aziz, Z., Nair, R., Seymour, L. (2011). Need for Global Partnership in Cancer Care: Perceptions of Cancer Care Researchers Attending the 2010 Australia and Asia Pacific Clinical Oncology Research Development Workshop. Journal of Oncology Practice, 7(5), 324-329. [More Information]
  • Chen, J., Hruby, G., Stockler, M., Patanjali, N., Bucci, J., Perez, G., Loadsman, J., Sheehan, E. (2011). Patient-reported outcomes of prostate high-dose-rate brachytherapy boost comparing an outpatient and inpatient protocol: A two-center chronologic cohort study. Brachytherapy, 10(6), 454-460. [More Information]
  • Hruby, G., Chen, J., Bucci, J., Loadsman, J., Perry, P., Stockler, M. (2011). Patients' experiences of high-dose-rate brachytherapy boost for prostate cancer using an inpatient protocol. Brachytherapy, 10(5), 395-400. [More Information]
  • Stockler, M. (2011). Quality of Life and Targeted Treatment for Metastatic Renal Cell Carcinoma. The Oncologist, 16(8), 1070-1071. [More Information]
  • Cox, K., Goel, S., O'Connell, R., Boyer, M., Beale, P., Simes, R., Stockler, M. (2011). Randomized cross-over trial comparing inpatient and outpatient administration of high-dose cisplatin. Internal Medicine Journal, 41(2), 172-178. [More Information]
  • Ooi, W., Stockler, M., Hayne, D. (2011). Re: Willem Oosterlinck, Ziya Kirkali, Richard Sylvester, et al. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC Genito-Urinary Group randomized phase 2 trial (30993). European Urology, 60(1), e1-e8. [More Information]
  • Kiely, B., Stockler, M., Tattersall, M. (2011). Thinking and talking about life expectancy in incurable cancer. Seminars in Oncology, 38(3), 380-385. [More Information]
  • Moore, M., Stockler, M., Lim, R., Mok, T., Millward, M., Boyer, M. (2010). A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group. Cancer Chemotherapy and Pharmacology, 66(5), 845-850. [More Information]
  • Lovell, M., Forder, P., Stockler, M., Butow, P., Briganti, E., Chye, R., Goldstein, D., Boyle, F. (2010). A Randomized Controlled Trial of a Standardized Educational Intervention for Patients with Cancer Pain. Journal of Pain and Symptom Management, 40(1), 49-59. [More Information]
  • Blinman, P., Duric, V., Nowak, A., Beale, P., Clarke, S., Briscoe, K., Boyce, A., Goldstein, D., Hudson, M., Stockler, M. (2010). Adjuvant chemotherapy for early colon cancer: What survival benefits make it worthwhile? European Journal of Cancer, 46(10), 1800-1807. [More Information]
  • Chim, L., Kelly, P., Salkeld, G., Stockler, M. (2010). Are Cancer Drugs Less Likely to be Recommended for Listing by the Pharmaceutical Benefits Advisory Committee in Australia? PharmacoEconomics, 28(6), 463-475. [More Information]
  • Tebbutt, N., Wilson, K., Gebski, V., Cummins, M., Zannino, D., van Hazel, G., Robinson, B., Broad, A., Ganju, V., Ackland, S., Stockler, M., Simes, R., et al (2010). Capecitabine, Bevacizumab and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized, Phase III MAX Study. Journal of Clinical Oncology, 28(19), 3191-3198. [More Information]
  • Kiely, B., Tattersall, M., Stockler, M. (2010). Certain Death in Uncertain Time: Informing Hope by Quantifying a Best Case Scenario. Journal of Clinical Oncology, 28(16), 2802-2804. [More Information]
  • Grimison, P., Stockler, M., Thomson, D., Olver, I., Harvey, V., Gebski, V., Lewis, C., Levi, J., Boyer, M., Gurney, H., Boland, A., Simes, R., et al (2010). Comparison of Two Standard Chemotherapy Regimens for Good-Prognosis Germ Cell Tumors: Updated Analysis of a Randomized Trial. Journal of the National Cancer Institute, 102(16), 1253-1262. [More Information]
  • Liu, S., Stockler, M., Lin, B. (2010). Five-Year Survival After Multimodal Approach in a Patient With Muscle-Invasive Transitional Cell Carcinoma of the Bladder and Adrenal Metastasis. UroToday International Journal, 3(5).
  • Lee, C., Lord, S., Stockler, M., Coates, A., Gebski, V., Simes, R. (2010). Historical cross-trial comparisons for competing treatments in advanced breast cancer - An empirical analysis of bias. European Journal of Cancer, 46(3), 541-548. [More Information]
  • King, M., Stockler, M., Cella, D., Osoba, D., Eton, D., Thompson, J., Eisenstein, A. (2010). Meta-analysis provides evidence-based effect sizes for a cancer-specific quality-of-life questionnaire, the FACT-G. Journal of Clinical Epidemiology, 63(3), 270-281. [More Information]
  • King, M., Cella, D., Osoba, D., Stockler, M., Eton, D., Thompson, J., Eisenstein, A. (2010). Meta-analysis provides evidence-based interpretation guidelines for the clinical significance of mean differences for the FACT-G, a cancer-specific quality of life questionnaire. Patient Related Outcome Measures, 1, 119-126. [More Information]
  • Blinman, P., Alam, M., Duric, V., McLachlan, S., Stockler, M. (2010). Patients' preferences for chemotherapy in non-small-cell lung cancer: A systematic review. Lung Cancer, 69(2), 141-147. [More Information]
  • Luckett, T., King, M., Stockler, M. (2010). Quality of life research in prostate and testicular cancer. Cancer Forum, 34(1), 20-23.
  • Tebbutt, N., Cummins, M., Sourjina, T., Strickland, A., van Hazel, G., Ganju, V., Gibbs, D., Stockler, M., Gebski, V., Zalcberg, J. (2010). Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. British Journal of Cancer, 102(3), 475-481.
  • Lee, C., Stockler, M., Coates, A., Gebski, V., Lord, S., Simes, R. (2010). Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer. British Journal of Cancer, 102(9), 1341-1347. [More Information]
  • Grimison, P., Simes, R., Hudson, M., Stockler, M. (2009). Deriving a Patient-Based Utility Index from a Cancer-Specific Quality of Life Questionnaire. Value in Health, 12(5), 800-807. [More Information]
  • Soon, Y., Stockler, M., Askie, L., Boyer, M. (2009). Duration of Chemotherapy for Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Trials. Journal of Clinical Oncology, 27(20), 3277-3283. [More Information]
  • Zhao, L., Lee, B., Brown, D., Molloy, M., Marx, G., Pavlakis, N., Boyer, M., Stockler, M., Kaplan, W., Breit, S., et al (2009). Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Research, 69(19), 7696-7703. [More Information]
  • Grimison, P., Simes, R., Hudson, M., Stockler, M. (2009). Preliminary Validation of an Optimally Weighted Patient-Based Utility Index by Application to Randomized Trials in Breast Cancer. Value in Health, 12(6), 967-976. [More Information]
  • Soon, Y., Stockler, M., Boyer, M. (2009). Reply to A.D. Sasse et al. Journal of Clinical Oncology, 27(35), e254. [More Information]
  • Barratt, A., Stockler, M. (2009). Screening for prostate cancer: explaining new trial results and their implications to patients. Medical Journal of Australia, 191(4), 226-229. [More Information]
  • Gill, G., Wetzig, N., Gebski, V., Stockler, M., Ung, O., Campbell, I., Simes, R. (2009). Sentinel-Lymph-Node-Based Management or Routine Axillary Clearance? One-Year Outcomes of Sentinel Node Biopsy Versus Axillary Clearance (SNAC): A Randomized Controlled Surgical Trial. Annals of Surgical Oncology, 16(2), 266-275. [More Information]
  • Stockler, M., March, L., Lindley, R., Mellis, C. (2009). Students' PEARLS: successfully incorporating evidence-based medicine in medical students' clinical attachments. Annals of Internal Medicine, 150(8), JC4-2-JC4-3. [More Information]
  • Friedlander, M., Butow, P., Stockler, M., Gainford, C., Martyn, J., Oza, A., Donovan, H., Miller, B., King, M. (2009). Symptom control in patients with recurrent ovarian cancer: measuring the benefit of palliative chemotherapy in women with platinum refractory/resistant ovarian cancer. International Journal Of Gynecological Cancer, 19(Suppl 2), S44-S48. [More Information]
  • Beslija, S., Bonneterre, J., Burstein, H., Cocquyt, V., Gnant, M., Heinemann, V., Jassem, J., Kostler, W., Krainer, M., Stockler, M., Wilcken, N. (2009). Third consensus on medical treatment of metastatic breast cancer. Annals of Oncology, 20(11), 1771-1785. [More Information]
  • Greaves, J., Glare, P., Kristjanson, L., Stockler, M., Tattersall, M. (2009). Undertreatment of nausea and other symptoms in hospitalized cancer patients. Supportive Care in Cancer, 17(4), 461-464. [More Information]
  • Nowak, A., Cebon, J., Hargreaves, C., Dhillon, H., Findlay, M., Gebski, V., Stockler, M. (2008). Assessment of health-related quality of life and patient benefit as outcome measures for clinical trials in hepatocellular carcinoma. Asia-Pacific Journal of Clinical Oncology, 4, 55-67.
  • Smith, M., Gill, P., Wetzig, N., Sourjina, T., Gebski, V., Ung, O., Campbell, I., Kollias, J., Coskinas, X., Macphee, A., Simes, R., Stockler, M., et al (2008). Comparing patients' and clinicians' assessment of outcomes in a randomised trial of sentinel node biopsy for breast cancer (the RACS SNAC trial). Breast Cancer Research and Treatment, Online (117)((1)), 1 (99)-11 (109). [More Information]
  • Duric, V., Butow, P., Sharpe, L., Heritier, S., Boyle, F., Beith, J., Wilcken, N., Coates, A., Simes, R., Stockler, M. (2008). Comparing patients' and their partners' preferences for adjuvant chemotherapy in early breast cancer. Patient Education and Counseling, 72(2), 239-245. [More Information]
  • Gainford, M., Yang, C., Liu, M., Stockler, M. (2008). Translation and cultural adaptation of the patient disease and treatment assessment form: A novel quality of life instrument for use in Taiwan. Asia-Pacific Journal of Clinical Oncology, 4(3), 149-156.
  • Lee, B., King, M., Simpson, J., Haran, M., Stockler, M., Marial, O., Salkeld, G. (2008). Validity, Responsiveness, and Minimal Important Difference for the SF-6D Health Utility Scale in a Spinal Cord Injured Population. Value in Health, 11(4), 680-688. [More Information]
  • Smith, M., Gill, P., Wetzig, N., Sourjina, T., Simes, R., Stockler, M. (2007). Bs06 patient-rated outcome measures were more sensitive than clinician-rated measures at distinguishing the effects of sentinel node biopsy and axillary clearance in the snac trial. ANZ Journal of Surgery, 77(Suppl. 1), A2-A2. [More Information]
  • Grimison, P., Simes, R., Stockler, M. (2007). Development and validation of optimally weighted measures of global health-related quality of life (QoL) and utility based on a cancer-specific QoL instrument. Value in Health, 10(6), A226-A227.
  • Stockler, M., O'Connell, R., Nowak, A., Goldstein, D., Turner, J., Wilcken, N., Wyld, D., Abdi, E., Glasgow, A., Beale, P., Dhillon, H., Heritier, S., Carter, C., Hickie, I., Simes, R., et al (2007). Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. Lancet Oncology, 8(7), 603-612. [More Information]
  • Wilcken, N., Stockler, M. (2007). Ovarian suppression for early breast cancer. The Lancet, 369, 1668-1670. [More Information]
  • Duric, V., Butow, P., Sharpe, L., Boyle, F., Beith, J., Wilcken, N., Heritier, S., Coates, A., Simes, R., Stockler, M. (2007). Psychosocial factors and patients' preferences for adjuvant chemotherapy in early breast cancer. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer, 16(1), 48-59. [More Information]
  • Grimison, P., Stockler, M. (2007). Quality of life and adjuvant systemic therapy for early-stage breast cancer. Expert Review of Anticancer Therapy, 7(8), 1123-1134. [More Information]
  • Beslija, S., Bonneterre, J., Burstein, H., Cocquyt, V., Gnant, M., Goodwin, P., Heinemann, V., Jassem, J., Kostler, W., Krainer, M., Stockler, M., Wilcken, N., et al (2007). Second consensus on medical treatment of metastatic breast cancer. Annals of Oncology, 18(2), 215-225. [More Information]
  • Stockler, M., Sourjina, T., Harvey, V., Frances, P., Byrne, M., van Hazel, G., Fitzharris, B., Ackland, S., Finch, K., Lindsay, D., Gebski, V., Simes, R., Coates, A., et al (2006). A randomized trial of capecitabine given intermittently versus continuously versus classical CMF as first line chemotherapy for women with advanced breast cancer unsuited to more intensive treatment. Breast Cancer Research and Treatment, 100(Supplement 1), S278-S278.
  • Pavlakis, N., Patel, D., Stockler, M. (2006). Biphosphonates in early prostate cancer. Cochrane Database of Systematic Reviews, 4, CD006249.
  • Stockler, M., Tattersall, M., Boyer, M., Clarke, S., Beale, P., Simes, R. (2006). Disarming the guarded prognosis: predicting survival in newly referred patients with incurable cancer. British Journal of Cancer, 94(2), 208-212. [More Information]
  • Charles (nee Slaviero), K., Rivory, L., Stockler, M., Beale, P., Beith, J., Boyer, M., Clarke, S. (2006). Predicting the toxicity of weekly docetaxel in advanced cancer. Clinical Pharmacokinetics, 45(6), 611-622. [More Information]
  • Hauser, C., Stockler, M., Tattersall, M. (2006). Prognostic factors in patients with recently diagnosed incurable cancer: a systematic review. Supportive Care in Cancer, 14, 999-1011. [More Information]
  • Gill, P., Gebski, V., Wetzig, N., Ung, O., Campbell, I., Collins, J., Sourjina, T., Coskinas, X., Stockler, M., Simes, R. (2006). Sentinel node (SN) based management causes less arm swelling and better quality of life than routine axillary clearance (AC): 1 year outcomes of the SNAC trial. Breast Cancer Research and Treatment, 100(Supplement 1), S14-S14.
  • Cebon, J., Hargreaves, C., Stockler, M., Boyer, M., Nowak, A., Dhillon, H., Gebski, V., Dickman, B., Findlay, M., Poon, A., et al (2006). Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. British Journal of Cancer, 95(7), 853-861. [More Information]
  • Stockler, M., Heritier, S., Nowak, A., Goldstein, D., Turner, J., Jefford, M., Glasgow, A., Abdi, E., Beale, P., Carter, C. (2006). The time taken to complete quality of life questionnaires in an advanced cancer trial. Journal of Clinical Oncology, 24(18S), 491s-491s.
  • Koczwara, B., Tattersall, M., Barton, M., Coventry, B., Dewar, J., Millar, J., Olver, I., Schwarz, M., Starmer, D., Turner, D., Stockler, M. (2005). Achieving equal standards in medical student education: is a national exit examination the answer? Medical Journal of Australia, 182(5), 228-230. [More Information]
  • Joshua, A., Celermajer, D., Stockler, M. (2005). Beauty is in the eye of the examiner: reaching agreement about physical signs and their value. Internal Medicine Journal, 35(3), 178-187. [More Information]
  • Pavlakis, N., Schmidt, R., Stockler, M. (2005). Bisphosphonates for breast cancer. Cochrane Database of Systematic Reviews, (3), CD003474. [More Information]
  • Duric, V., Stockler, M., Butow, P., Sharpe, L., Heritier, S., Beith, J., Boyle, F., Wilcken, N., Coates, A., Simes, R. (2005). Comparing patients' and their partners' preferences for adjuvant chemotherapy (ACT) in early breast cancer (EBC). Journal of Clinical Oncology, 23(16S), 546S-546S.
  • Haran, M., Lee, B., King, M., Marial, O., Stockler, M. (2005). Health status rated with the Medical Outcomes Study 36-Item Short-Form Health Survey after spinal cord injury. Archives of Physical Medicine and Rehabilitation, 86(12), 2290-2295. [More Information]
  • Medd, J., Stockler, M., Collins, R., Lalak, A. (2005). Measuring men's opinions of prostate needle biopsy. ANZ Journal of Surgery, 75(8), 662-664. [More Information]
  • Wetzig, N., Gill, P., Ung, O., Collins, J., Kollias, J., Gillett, D., Gebski, V., Greig, C., Ray, A., Stockler, M. (2005). Participation in the RACS sentinel node biopsy versus axillary clearance trial. ANZ Journal of Surgery, 75(3), 98-100. [More Information]
  • Duric, V., Stockler, M., Heritier, S., Boyle, F., Beith, J., Sullivan, A., Wilcken, N., Coates, A., Simes, R. (2005). Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now? Annals of Oncology, 16(11), 1786-1794. [More Information]
  • Duric, V., Fallowfield, L., Saunders, C., Houghton, J., Coates, A., Stockler, M. (2005). Patients' preferences for adjuvant endocrine therapy in early breast cancer: what makes it worthwhile? British Journal of Cancer, 93(12), 1319-1323. [More Information]
  • Stockler, M. (2005). Review: bisphosphonates are modestly better than placebo for relieving painful bone metastases. ACP Journal Club, 143(1), 13. [More Information]
  • Nowak, A., Stockler, M., Chow, P., Findlay, M. (2005). Use of Tamoxifen in Advanced-Stage Hepatocellular Carcinoma. Cancer, 103(7), 1408-1414. [More Information]
  • Joshua, A., Nordman, I., Venkataswaran, R., Clarke, S., Stockler, M., Boyer, M. (2005). Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer. Internal Medicine Journal, 35(8), 468-472. [More Information]
  • Thewes, B., Meiser, B., Duric, V., Stockler, M., Taylor, A., Stuart-Harris, R., Links, M., Wilcken, N., McLachlan, S., Phillips, K., Boyle, F., et al (2005). What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile? Lancet Oncology, 6(8), 581-588. [More Information]
  • Cox, K., O'Connell, R., Stockler, M., Boyer, M., Beale, P., Simes, R. (2004). A randomized crossover trial of giving high-dose cisplatin with or without an overnight stay in hospital: Patients' preferences, quality of life, safety and resource use. Journal of Clinical Oncology, 22(14S), 547S-547S.
  • Stockler, M., Vardy, J., Pillai, A., Warr, D. (2004). Acetaminophen (Paracetamol) Improves Pain And Well-Being In People With Advanced Cancer Already Receiving A Strong Opioid Regimen: A Randomized, Double-Blind, Placebo-Controlled Cross-Over Trial. Journal of Clinical Oncology, 22(16), 3389-3394.
  • Nowak, A., Stockler, M., Byrne, M. (2004). Assessing Quality Of Life During Chemotherapy For Pleural Mesothelioma: Feasibility, Validity, And Results Of Using The European Organization For Research And Treatment Of Cancer Core Quality Of Life Questionnaire And Lung Cancer Module. Journal of Clinical Oncology, 22(15), 3172-3180.
  • Vardy, J., Engelhardt, K., Cox, K., Jacquet, J., McDade, A., Boyer, M., Beale, P., Clarke, S., Stockler, M., Loneragan, R., Waugh, R., Clarke, S. (2004). Long-Term Outcome Of Radiological-Guided Insertion Of Implanted Central Venous Access Port Devices (Cvapd) For The Delivery Of Chemotherapy In Cancer Patients: Institutional Experience And Review Of The Literature. British Journal of Cancer, 91(6), 1045-1049.
  • Duric, V., Stockler, M., Butow, P., Sharpe, L., Beith, J., Sullivan, A., Boyle, F., Dhillon, H., Coates, A., Simes, R. (2004). Predictors of the benefits women consider necessary to make adjuvant chemotherapy (ACT) worthwhile for early breast cancer (EBC). Journal of Clinical Oncology, 22(14S), 73S-73S.
  • Joshua, A., Stockler, M., Boyer, M. (2004). Prolonged survival after the diagnosis of metastatic hepatic epitheliod haemangioendothelioma. Internal Medicine Journal, 34(1-2), 70-71.
  • Nowak, A., Wilcken, N., Stockler, M., Hamilton, A., Ghersi, D. (2004). Systematic Review Of Taxane-Containing Versus Non-Taxane-Containing Regimens For Adjuvant And Neoadjuvant Treatment Of Early Breast Cancer. Lancet Oncology, 5(6), 372-380.
  • Glare, P., Pereira, G., Kristjanson, L., Stockler, M., Tattersall, M. (2004). Systematic Review Of The Efficacy Of Antiemetics In The Treatment Of Nausea In Patients With Far-Advanced Cancer. Supportive Care in Cancer, 12(6), 432-440. [More Information]
  • Pavlakis, N., Stockler, M. (2003). Bisphosphonates for breast cancer. Cochrane Database of Systematic Reviews, 11.
  • Stockler, M., Wilcken, N., Coates, A. (2003). Chemotherapy for advanced breast cancer- how long should it continue? Breast Cancer Research and Treatment, 81(Suppl 1), S49-S52.
  • Beslija, S., Bonneterre, J., Burstein, H., Gnant, M., Goodwin, P., Heinemann, V., Jassem, J., Köstler, W., Krainer, M., Menard, S., Stockler, M., et al (2003). Consensus on medical treatment of metastatic breast cancer. Breast Cancer Research and Treatment, 81(Supplement 1), S1-S7.
  • Wilcken, N., Stockler, M. (2003). Fulvestrant: spreading the word, but not too thinly. The Lancet, 11, 1254-1254.
  • Jefford, M., Stockler, M., Tattersall, M. (2003). Outcomes research: what is it and why does it matter? Internal Medicine Journal, 33(3), 110-118.
  • Eckermann, S., Martin, A., Stockler, M., Simes, R. (2003). The benefits and costs of tamoxifen for breast cancer prevention. Australian and New Zealand Journal of Public Health, 27(1), 34-40.
  • Boyer, M., Stockler, M., Rosenthal, M., Eisinger, D., Goad, J., Webb, D. (2002). Adjuvant mitoxantrone chemotherapy for men at high risk of relapse following radical prostatectomy: a pilot study. UroOncology, 2(1), 15-17.
  • Pavlakis, N., Stockler, M. (2002). Bisphosphonates in breast cancer. Cochrane Database of Systematic Reviews, , 1-28.
  • Horvath, L., McCaughan, B., Stockler, M., Boyer, M. (2002). Resection of residual pulmonary masses after chemotherapy in patients with metastatic non-seminomatous germ cell tumours. Internal Medicine Journal, 32(3), 79-83.
  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, C., Liberati, A., et al (2001). Addition of drug/s to a chemotherapy regimen for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Basser, R., Henderson, I., Brunswick, C., Fossati, R., Liberati, A., et al (2001). Antitumor antibiotic containing regimins for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
  • Toner, G., Stockler, M., Boyer, M., Jones, M., Thomson, D., Harvey, V., Olver, I., Dhillon, H., McMullen, A., Gebski, V., Levi, J., Simes, R. (2001). Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. The Lancet, 357(9528), 739-745.
  • Craig, J., Irwig, L., Stockler, M. (2001). Evidence-based medicine: useful tools for decision making. Medical Journal of Australia, 174, 248-253.
  • Gooden, B., Smith, M., Tattersall, S., Stockler, M. (2001). Hospitalised patients' views on doctors and white coats. Medical Journal of Australia, 175, 219-222.
  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, R., Liberati, A., et al (2001). Larger vs smaller dose of the same drug/s regimen for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
  • Duric, V., Stockler, M. (2001). Patients' preferences for adjuvant chemotherapy in early breast cancer: a review of what makes it worthwhile? Lancet Oncology, 2(11), 691-697.
  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, R., Liberati, A., et al (2001). Platinum containing reimens for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, R., Liberati, A., et al (2001). Single agent vs combination chemotherapy for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, C., Liberati, A., et al (2001). Taxane containing regimens for metastatsic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, R., Liberati, A., et al (2001). Two drug combinations vs combinations of 3 or more cytotoxic drugs for meastatic brest cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
  • Stockler, M., Wilcken, N., Ghersi, D., Simes, R. (2000). Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treatment Reviews, 26(3), 151-168.

Conferences

  • Kiely, B., Lee, C., Tattersall, M., Stockler, M. (2010). How long have I got? Estimating post-progression survival after first line chemotherapy for metastatic breast cancer based on data from randomized trials. 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.
  • Kiely, B., Soon, Y., Tattersall, M., Stockler, M. (2010). How long have I got? Estimating survival for women starting first-line chemotherapy for metastatic breast cancer (MBC): A systematic review of recent randomized trials. 2010 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • Clarke, S., Boyer, M., Stockler, M., Venkatawaran, R., Nordman, I., Joshua, A. (2005). Weekly docetaxel as second line treatment after mitoxantrone for androgen-independent prostate cancer (AIPC). 2005 ASCO Annual Meeting, NY, USA: American Society of Clinical Oncology.
  • Wetzig, N., Gill, P., Ung, O., Collins, J., Kollias, J., Gillette, D., Gebski, V., Greig, C., Ray, A., Stockler, M. (2002). Eligibility and Choice in the royal Australiasian College of Surgeons "SNAC Trial" of Sentinel Node Biopsy versus axillary clearance in operable breast cancer. 3rd International Sentinel Node Congress.
  • Craig, J., Irwig, L., Stockler, M., Barratt, A., Cumming, R., Caplehorn, J. (2001). Clinical epidemiology education: to help culture change now and generate new research later. 4th International Conference on the Scientific Basis of Health Services.

2014

  • Grimison, P., Stockler, M., Chatfield, M., Thomson, D., Gebski, V., Friedlander, M., Boland, A., Houghton, B., Gruney, H., Rosenthal, M., et al (2014). Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Annals of Oncology, 25(1), 143-148. [More Information]
  • Lin, H., Castillo, L., Mahon, K., Chiam, K., Lee, B., Nguyen, Q., Boyer, M., Stockler, M., Pavlakis, N., Marx, G., Gurney, H., Horvath, L., et al (2014). Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. British Journal of Cancer, 110(10), 2462-2471. [More Information]
  • King, M., Stockler, M., Butow, P., O'Connell, R., Voysey, M., Oza, A., Gillies, K., Donovan, H., Mercieca-Bebber, R., Martyn, J., Sjoquist, K., Friedlander, M. (2014). Development of the measure of ovarian symptoms and treatment concerns: aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancer. International Journal of Gynecological Cancer, 24(5), 865-873. [More Information]
  • West, T., Kiely, B., Stockler, M. (2014). Estimating scenarios for survival time in men starting systemic therapies for castration-resistant prostate cancer: A systematic review of randomised trials. European Journal of Cancer, 50(11), 1916-1924. [More Information]
  • Stockler, M., Hilpert, F., Friedlander, M., King, M., Wenzel, L., Lee, C., Joly, F., de Gregorio, N., Arranz, J., Mirza, M., et al (2014). Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer. Journal of Clinical Oncology, 32(13), 1309-1316. [More Information]
  • Laurie, S., Solomon, B., Seymour, L., Ellis, P., Goss, G., Shepherd, F., Boyer, M., Arnold, A., Clingan, P., Laberge, F., Stockler, M., Lee, C., et al (2014). Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29. European Journal of Cancer, 50(4), 706-712. [More Information]
  • Karikios, D., Schofield, D., Salkeld, G., Mann, K., Trotman, J., Stockler, M. (2014). Rising cost of anticancer drugs in Australia. Internal Medicine Journal, 44(5), 458-463. [More Information]
  • Beumer, J., Gill, G., Campbell, I., Wetzig, N., Ung, O., Farshid, G., Uren, R., Stockler, M., Gebski, V. (2014). Sentinel node biopsy and large (≥3 cm) breast cancer. ANZ Journal of Surgery, 84(3), 117-120. [More Information]
  • Friedlander, M., Stockler, M., O'Connell, R., Voysey, M., Oza, A., Gillies, K., Donovan, H., Martyn, J., Sjoquist, K., Butow, P., King, M., et al (2014). Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit study. International Journal of Gynecological Cancer, 24(5), 857-864. [More Information]

2013

  • Nowak, A., Brown, C., Millward, M., Creaney, J., Byrne, M., Hughes, B., Kremmidiotis, G., Bibby, D., Leske, A., Mitchell, P., Pavlakis, N., Stockler, M., et al (2013). A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. Lung Cancer, 81(3), 422-427. [More Information]
  • McCaughan, G., Blinman, P., Boyer, M., Stockler, M. (2013). Better estimates of survival for patients considering adjuvant chemotherapy after surgery for early non-small-cell lung cancer. Internal Medicine Journal, 43(4), 424-429. [More Information]
  • Gzell, C., Kench, J., Stockler, M., Hruby, G. (2013). Biopsy-proven brain metastases from prostate cancer: a series of four cases with review of the literature. International Urology and Nephrology, 45(3), 735-742. [More Information]
  • Friedlander, M., Stockler, M., Butow, P., King, M., McAlpine, J., Tinker, A., Ledermann, J. (2013). Clinical Trials of Palliative Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: Time to Think Differently? Journal of Clinical Oncology, 31(18), 2362. [More Information]
  • Blinman, P., Gainford, C., Donoghoe, M., Martyn, J., Bloomfield, P., Grant, P., Kichenadasse, G., Vaughan, M., Brand, A., Shannon, C., Gebski, V., Stockler, M., et al (2013). Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study. Journal of Gynecologic Oncology, 24(4), 359-366. [More Information]
  • Sjoquist, K., Friedlander, M., O'Connell, R., Voysey, M., King, M., Stockler, M., Oza, A., Gillies, K., Martyn, J., Butow, P. (2013). Hope, Quality of Life, and Benefit From Treatment in Women Having Chemotherapy for Platinum-Resistant/Refractory Recurrent Ovarian Cancer: The Gynecological Cancer Intergroup Symptom Benefit Study. The Oncologist, 18(11), 1221-1228. [More Information]
  • Stockler, M. (2013). Intermittent and continuous androgen deprivation did not differ for mortality after radiotherapy for prostate cancer. Annals of Internal Medicine, 158(2), JC9. [More Information]
  • Houghton, B., Chalasani, V., Hayne, D., Grimison, P., Brown, C., Patel, M., Davis, I., Stockler, M. (2013). Intravesical chemotherapy plus bacille Calmette-Guerin in non-muscle invasive bladder cancer: a systematic review with meta-analysis. BJU International, 111(6), 977-933. [More Information]
  • Coupe, N., Cox, K., Clark, K., Boyer, M., Stockler, M. (2013). Outcomes of Permanent Peritoneal Ports for the Management of Recurrent Malignant Ascites. Journal of Palliative Medicine, 16(8), 938-940. [More Information]
  • Grimison, P., Houghton, B., Chatfield, M., Toner, G., Davis, I., Martin, J., Hovey, E., Stockler, M. (2013). Patterns of management and surveillance imaging amongst medical oncologists in Australia for stage I testicular cancer. BJU International, 112(2), E35-E43. [More Information]
  • Price, M., Bell, M., Sommeijer, D., Friedlander, M., Stockler, M., deFazio, A., Webb, P., Butow, P. (2013). Physical symptoms, coping styles and quality of life in recurrent ovarian cancer: A prospective population-based study over the last year of life. Gynecologic Oncology, 130(1), 162-168. [More Information]
  • Olver, I., Grimison, P., Chatfield, M., Stockler, M., Toner, G., Gebski, V., Harrup, R., Underhill, C., Kichenadasse, G., Singhal, N., Boland, A., McDonald, A., et al (2013). Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy. Supportive Care in Cancer, 21(6), 1561-1568. [More Information]
  • Martin, A., Lord, S., Verry, H., Stockler, M., Emery, J. (2013). Risk assessment to guide prostate cancer screening decisions: a cost-effectiveness analysis. Medical Journal of Australia, 198(10), 546-550. [More Information]
  • Stark, D., Nankivell, M., Pujade-Lauraine, E., Kristensen, G., Elit, L., Stockler, M., Hilpert, F., Cervantes, A., Brown, J., Lanceley, A., et al (2013). Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncology, 14(3), 236-243. [More Information]
  • Thientosapol, E., Tran, T., Della-Fiorentina, S., Adams, D., Chantrill, L., Stockler, M., Kiely, B. (2013). Survival times of women with metastatic breast cancer starting first-line chemotherapy in routine clinical practice versus contemporary randomised trials. Internal Medicine Journal, 43(8), 883-888. [More Information]
  • Kiely, B., Martin, A., Tattersall, M., Nowak, A., Goldstein, D., Wilcken, N., Wyld, D., Abdi, E., Glasgow, A., Beale, P., Stockler, M., et al (2013). The Median Informs the Message: Accuracy of Individualized Scenarios for Survival Time Based on Oncologists' Estimates. Journal of Clinical Oncology, 31(28), 3565-3571. [More Information]
  • Smith, A., King, M., Butow, P., Luckett, T., Grimison, P., Toner, G., Stockler, M., Hovey, E., Stubbs, J., Hruby, G., Gurney, H., Turner, S., et al (2013). The prevalence and correlates of supportive care needs in testicular cancer survivors: a cross-sectional study. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer, 22(11), 2557-2564. [More Information]
  • Kiely, B., McCaughan, G., Christodoulou, S., Beale, P., Grimison, P., Trotman, J., Tattersall, M., Stockler, M. (2013). Using scenarios to explain life expectancy in advanced cancer: attitudes of people with a cancer experience. Supportive Care in Cancer, 21(2), 369-376. [More Information]

2012

  • Wong, M., Stockler, M., Pavlakis, N. (2012). Bisphosphonates and other bone agents for breast cancer (Review). The Cochrane Library Chichester UK: John Wiley and Sons Ltd, 2, 1-136. [More Information]
  • Kiely, B., Alam, M., Blinman, P., Tattersall, M., Stockler, M. (2012). Estimating typical, best-case and worst-case life expectancy scenarios for patients starting chemotherapy for advanced non-small-cell lung cancer: A systematic review of contemporary randomized trials. Lung Cancer, 77(3), 537-544. [More Information]
  • Wilcken, N., Stockler, M. (2012). Individual patient meta-analysis: Taxane plus anthracycline reduces mortality from early breast cancer. Annals of Internal Medicine, 156(12), 432-444.
  • Kiely, B., Stockler, M. (2012). Meta-analysis: Adjuvant tamoxifen reduces recurrence and death at 15 years in ER-positive early breast cancer. Annals of Internal Medicine, 156(6), JC3-4-JC3-4. [More Information]
  • Blinman, P., King, M., Norman, R., Viney, R., Stockler, M. (2012). Preferences for cancer treatments: An overview of methods and applications in oncology. Annals of Oncology, 23(5), 1104-1110. [More Information]
  • King, M., Viney, R., Smith, D., Hossain, I., Street, D., Savage, E., Fowler, S., Berry, M., Stockler, M., Cozzi, P., Armstrong, B., et al (2012). Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer. British Journal of Cancer, 106(4), 638-645. [More Information]
  • Stockler, M., Wilcken, N. (2012). Why Is Management of Cancer Pain Still a Problem? Journal of Clinical Oncology, 30(16), 1907-1908. [More Information]

2011

  • Lee, C., Hudson, M., Stockler, M., Coates, A., Ackland, S., Gebski, V., Lord, S., Friedlander, M., Boyle, F., Simes, R. (2011). A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer. Breast Cancer Research and Treatment, 129(2), 467-476. [More Information]
  • Stockler, M., Harvey, V., Francis, P., Byrne, M., Ackland, S., Fitzharris, B., Van Hazel, G., Wilcken, N., Grimison, P., Nowak, A., Zannino, D., Gebski, V., Coates, A., et al (2011). Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer. Journal of Clinical Oncology, 29(34), 4498-4504. [More Information]
  • Gennari, A., Stockler, M., Puntoni, M., Sormani, M., Nanni, O., Amadori, D., Wilcken, N., D'Amico, M., DeCensi, A., Bruzzi, P. (2011). Duration of Chemotherapy for Metastatic Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Journal of Clinical Oncology, 29(16), 2144-2149. [More Information]
  • Kiely, B., Soon, Y., Tattersall, M., Stockler, M. (2011). How Long Have I Got? Estimating Typical, Best-Case, and Worst-Case Scenarios for Patients Starting First-Line Chemotherapy for Metastatic Breast Cancer: A Systematic Review of Recent Randomized Trials. Journal of Clinical Oncology, 29(4), 456-463. [More Information]
  • Kiely, B., Wilcken, N., Stockler, M. (2011). Life after adjuvant chemotherapy for breast cancer: the news is mostly good. Journal of Clinical Oncology, 29(9), 1092-1093. [More Information]
  • Blinman, P., McLachlan, S., Nowak, A., Duric, V., Brown, C., Wright, G., Millward, M., Fong, K., Stockler, M. (2011). Lung cancer clinicians' preferences for adjuvant chemotherapy in non-small-cell lung cancer: What makes it worthwhile? Lung Cancer, 72(2), 213-218. [More Information]
  • Lyerly, H., Abernethy, A., Stockler, M., Koczwara, B., Aziz, Z., Nair, R., Seymour, L. (2011). Need for Global Partnership in Cancer Care: Perceptions of Cancer Care Researchers Attending the 2010 Australia and Asia Pacific Clinical Oncology Research Development Workshop. Journal of Oncology Practice, 7(5), 324-329. [More Information]
  • Chen, J., Hruby, G., Stockler, M., Patanjali, N., Bucci, J., Perez, G., Loadsman, J., Sheehan, E. (2011). Patient-reported outcomes of prostate high-dose-rate brachytherapy boost comparing an outpatient and inpatient protocol: A two-center chronologic cohort study. Brachytherapy, 10(6), 454-460. [More Information]
  • Hruby, G., Chen, J., Bucci, J., Loadsman, J., Perry, P., Stockler, M. (2011). Patients' experiences of high-dose-rate brachytherapy boost for prostate cancer using an inpatient protocol. Brachytherapy, 10(5), 395-400. [More Information]
  • Stockler, M. (2011). Quality of Life and Targeted Treatment for Metastatic Renal Cell Carcinoma. The Oncologist, 16(8), 1070-1071. [More Information]
  • Cox, K., Goel, S., O'Connell, R., Boyer, M., Beale, P., Simes, R., Stockler, M. (2011). Randomized cross-over trial comparing inpatient and outpatient administration of high-dose cisplatin. Internal Medicine Journal, 41(2), 172-178. [More Information]
  • Ooi, W., Stockler, M., Hayne, D. (2011). Re: Willem Oosterlinck, Ziya Kirkali, Richard Sylvester, et al. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC Genito-Urinary Group randomized phase 2 trial (30993). European Urology, 60(1), e1-e8. [More Information]
  • Kiely, B., Stockler, M., Tattersall, M. (2011). Thinking and talking about life expectancy in incurable cancer. Seminars in Oncology, 38(3), 380-385. [More Information]

2010

  • Moore, M., Stockler, M., Lim, R., Mok, T., Millward, M., Boyer, M. (2010). A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group. Cancer Chemotherapy and Pharmacology, 66(5), 845-850. [More Information]
  • Lovell, M., Forder, P., Stockler, M., Butow, P., Briganti, E., Chye, R., Goldstein, D., Boyle, F. (2010). A Randomized Controlled Trial of a Standardized Educational Intervention for Patients with Cancer Pain. Journal of Pain and Symptom Management, 40(1), 49-59. [More Information]
  • Blinman, P., Duric, V., Nowak, A., Beale, P., Clarke, S., Briscoe, K., Boyce, A., Goldstein, D., Hudson, M., Stockler, M. (2010). Adjuvant chemotherapy for early colon cancer: What survival benefits make it worthwhile? European Journal of Cancer, 46(10), 1800-1807. [More Information]
  • Chim, L., Kelly, P., Salkeld, G., Stockler, M. (2010). Are Cancer Drugs Less Likely to be Recommended for Listing by the Pharmaceutical Benefits Advisory Committee in Australia? PharmacoEconomics, 28(6), 463-475. [More Information]
  • Tebbutt, N., Wilson, K., Gebski, V., Cummins, M., Zannino, D., van Hazel, G., Robinson, B., Broad, A., Ganju, V., Ackland, S., Stockler, M., Simes, R., et al (2010). Capecitabine, Bevacizumab and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized, Phase III MAX Study. Journal of Clinical Oncology, 28(19), 3191-3198. [More Information]
  • Kiely, B., Tattersall, M., Stockler, M. (2010). Certain Death in Uncertain Time: Informing Hope by Quantifying a Best Case Scenario. Journal of Clinical Oncology, 28(16), 2802-2804. [More Information]
  • Grimison, P., Stockler, M., Thomson, D., Olver, I., Harvey, V., Gebski, V., Lewis, C., Levi, J., Boyer, M., Gurney, H., Boland, A., Simes, R., et al (2010). Comparison of Two Standard Chemotherapy Regimens for Good-Prognosis Germ Cell Tumors: Updated Analysis of a Randomized Trial. Journal of the National Cancer Institute, 102(16), 1253-1262. [More Information]
  • Liu, S., Stockler, M., Lin, B. (2010). Five-Year Survival After Multimodal Approach in a Patient With Muscle-Invasive Transitional Cell Carcinoma of the Bladder and Adrenal Metastasis. UroToday International Journal, 3(5).
  • Lee, C., Lord, S., Stockler, M., Coates, A., Gebski, V., Simes, R. (2010). Historical cross-trial comparisons for competing treatments in advanced breast cancer - An empirical analysis of bias. European Journal of Cancer, 46(3), 541-548. [More Information]
  • Kiely, B., Lee, C., Tattersall, M., Stockler, M. (2010). How long have I got? Estimating post-progression survival after first line chemotherapy for metastatic breast cancer based on data from randomized trials. 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.
  • Kiely, B., Soon, Y., Tattersall, M., Stockler, M. (2010). How long have I got? Estimating survival for women starting first-line chemotherapy for metastatic breast cancer (MBC): A systematic review of recent randomized trials. 2010 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • Chapman, S., Barratt, A., Stockler, M. (2010). Let sleeping dogs lie What men should know before getting tested for prostate cancer. Sydney: Sydney University Press.
  • King, M., Stockler, M., Cella, D., Osoba, D., Eton, D., Thompson, J., Eisenstein, A. (2010). Meta-analysis provides evidence-based effect sizes for a cancer-specific quality-of-life questionnaire, the FACT-G. Journal of Clinical Epidemiology, 63(3), 270-281. [More Information]
  • King, M., Cella, D., Osoba, D., Stockler, M., Eton, D., Thompson, J., Eisenstein, A. (2010). Meta-analysis provides evidence-based interpretation guidelines for the clinical significance of mean differences for the FACT-G, a cancer-specific quality of life questionnaire. Patient Related Outcome Measures, 1, 119-126. [More Information]
  • Blinman, P., Alam, M., Duric, V., McLachlan, S., Stockler, M. (2010). Patients' preferences for chemotherapy in non-small-cell lung cancer: A systematic review. Lung Cancer, 69(2), 141-147. [More Information]
  • Luckett, T., King, M., Stockler, M. (2010). Quality of life research in prostate and testicular cancer. Cancer Forum, 34(1), 20-23.
  • Tebbutt, N., Cummins, M., Sourjina, T., Strickland, A., van Hazel, G., Ganju, V., Gibbs, D., Stockler, M., Gebski, V., Zalcberg, J. (2010). Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. British Journal of Cancer, 102(3), 475-481.
  • Lee, C., Stockler, M., Coates, A., Gebski, V., Lord, S., Simes, R. (2010). Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer. British Journal of Cancer, 102(9), 1341-1347. [More Information]

2009

  • Grimison, P., Simes, R., Hudson, M., Stockler, M. (2009). Deriving a Patient-Based Utility Index from a Cancer-Specific Quality of Life Questionnaire. Value in Health, 12(5), 800-807. [More Information]
  • Soon, Y., Stockler, M., Askie, L., Boyer, M. (2009). Duration of Chemotherapy for Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Trials. Journal of Clinical Oncology, 27(20), 3277-3283. [More Information]
  • Zhao, L., Lee, B., Brown, D., Molloy, M., Marx, G., Pavlakis, N., Boyer, M., Stockler, M., Kaplan, W., Breit, S., et al (2009). Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Research, 69(19), 7696-7703. [More Information]
  • Grimison, P., Simes, R., Hudson, M., Stockler, M. (2009). Preliminary Validation of an Optimally Weighted Patient-Based Utility Index by Application to Randomized Trials in Breast Cancer. Value in Health, 12(6), 967-976. [More Information]
  • Soon, Y., Stockler, M., Boyer, M. (2009). Reply to A.D. Sasse et al. Journal of Clinical Oncology, 27(35), e254. [More Information]
  • Barratt, A., Stockler, M. (2009). Screening for prostate cancer: explaining new trial results and their implications to patients. Medical Journal of Australia, 191(4), 226-229. [More Information]
  • Gill, G., Wetzig, N., Gebski, V., Stockler, M., Ung, O., Campbell, I., Simes, R. (2009). Sentinel-Lymph-Node-Based Management or Routine Axillary Clearance? One-Year Outcomes of Sentinel Node Biopsy Versus Axillary Clearance (SNAC): A Randomized Controlled Surgical Trial. Annals of Surgical Oncology, 16(2), 266-275. [More Information]
  • Stockler, M., March, L., Lindley, R., Mellis, C. (2009). Students' PEARLS: successfully incorporating evidence-based medicine in medical students' clinical attachments. Annals of Internal Medicine, 150(8), JC4-2-JC4-3. [More Information]
  • Friedlander, M., Butow, P., Stockler, M., Gainford, C., Martyn, J., Oza, A., Donovan, H., Miller, B., King, M. (2009). Symptom control in patients with recurrent ovarian cancer: measuring the benefit of palliative chemotherapy in women with platinum refractory/resistant ovarian cancer. International Journal Of Gynecological Cancer, 19(Suppl 2), S44-S48. [More Information]
  • Beslija, S., Bonneterre, J., Burstein, H., Cocquyt, V., Gnant, M., Heinemann, V., Jassem, J., Kostler, W., Krainer, M., Stockler, M., Wilcken, N. (2009). Third consensus on medical treatment of metastatic breast cancer. Annals of Oncology, 20(11), 1771-1785. [More Information]
  • Greaves, J., Glare, P., Kristjanson, L., Stockler, M., Tattersall, M. (2009). Undertreatment of nausea and other symptoms in hospitalized cancer patients. Supportive Care in Cancer, 17(4), 461-464. [More Information]

2008

  • Nowak, A., Cebon, J., Hargreaves, C., Dhillon, H., Findlay, M., Gebski, V., Stockler, M. (2008). Assessment of health-related quality of life and patient benefit as outcome measures for clinical trials in hepatocellular carcinoma. Asia-Pacific Journal of Clinical Oncology, 4, 55-67.
  • Smith, M., Gill, P., Wetzig, N., Sourjina, T., Gebski, V., Ung, O., Campbell, I., Kollias, J., Coskinas, X., Macphee, A., Simes, R., Stockler, M., et al (2008). Comparing patients' and clinicians' assessment of outcomes in a randomised trial of sentinel node biopsy for breast cancer (the RACS SNAC trial). Breast Cancer Research and Treatment, Online (117)((1)), 1 (99)-11 (109). [More Information]
  • Duric, V., Butow, P., Sharpe, L., Heritier, S., Boyle, F., Beith, J., Wilcken, N., Coates, A., Simes, R., Stockler, M. (2008). Comparing patients' and their partners' preferences for adjuvant chemotherapy in early breast cancer. Patient Education and Counseling, 72(2), 239-245. [More Information]
  • Butow, P., Hagerty, R., Tattersall, M., Stockler, M. (2008). Foretelling: Communicating the prognosis. In N. Christakis and P. Glare (Eds.), Prognosis in Advanced Cancer, (pp. 33-53). Oxford: Oxford University Press.
  • Gainford, M., Yang, C., Liu, M., Stockler, M. (2008). Translation and cultural adaptation of the patient disease and treatment assessment form: A novel quality of life instrument for use in Taiwan. Asia-Pacific Journal of Clinical Oncology, 4(3), 149-156.
  • Lee, B., King, M., Simpson, J., Haran, M., Stockler, M., Marial, O., Salkeld, G. (2008). Validity, Responsiveness, and Minimal Important Difference for the SF-6D Health Utility Scale in a Spinal Cord Injured Population. Value in Health, 11(4), 680-688. [More Information]

2007

  • Smith, M., Gill, P., Wetzig, N., Sourjina, T., Simes, R., Stockler, M. (2007). Bs06 patient-rated outcome measures were more sensitive than clinician-rated measures at distinguishing the effects of sentinel node biopsy and axillary clearance in the snac trial. ANZ Journal of Surgery, 77(Suppl. 1), A2-A2. [More Information]
  • Grimison, P., Simes, R., Stockler, M. (2007). Development and validation of optimally weighted measures of global health-related quality of life (QoL) and utility based on a cancer-specific QoL instrument. Value in Health, 10(6), A226-A227.
  • Stockler, M., O'Connell, R., Nowak, A., Goldstein, D., Turner, J., Wilcken, N., Wyld, D., Abdi, E., Glasgow, A., Beale, P., Dhillon, H., Heritier, S., Carter, C., Hickie, I., Simes, R., et al (2007). Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. Lancet Oncology, 8(7), 603-612. [More Information]
  • Wilcken, N., Stockler, M. (2007). Ovarian suppression for early breast cancer. The Lancet, 369, 1668-1670. [More Information]
  • Duric, V., Butow, P., Sharpe, L., Boyle, F., Beith, J., Wilcken, N., Heritier, S., Coates, A., Simes, R., Stockler, M. (2007). Psychosocial factors and patients' preferences for adjuvant chemotherapy in early breast cancer. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer, 16(1), 48-59. [More Information]
  • Grimison, P., Stockler, M. (2007). Quality of life and adjuvant systemic therapy for early-stage breast cancer. Expert Review of Anticancer Therapy, 7(8), 1123-1134. [More Information]
  • Beslija, S., Bonneterre, J., Burstein, H., Cocquyt, V., Gnant, M., Goodwin, P., Heinemann, V., Jassem, J., Kostler, W., Krainer, M., Stockler, M., Wilcken, N., et al (2007). Second consensus on medical treatment of metastatic breast cancer. Annals of Oncology, 18(2), 215-225. [More Information]

2006

  • Stockler, M., Sourjina, T., Harvey, V., Frances, P., Byrne, M., van Hazel, G., Fitzharris, B., Ackland, S., Finch, K., Lindsay, D., Gebski, V., Simes, R., Coates, A., et al (2006). A randomized trial of capecitabine given intermittently versus continuously versus classical CMF as first line chemotherapy for women with advanced breast cancer unsuited to more intensive treatment. Breast Cancer Research and Treatment, 100(Supplement 1), S278-S278.
  • Pavlakis, N., Patel, D., Stockler, M. (2006). Biphosphonates in early prostate cancer. Cochrane Database of Systematic Reviews, 4, CD006249.
  • Stockler, M., Tattersall, M., Boyer, M., Clarke, S., Beale, P., Simes, R. (2006). Disarming the guarded prognosis: predicting survival in newly referred patients with incurable cancer. British Journal of Cancer, 94(2), 208-212. [More Information]
  • Stockler, M., Duric, V., Coates, A. (2006). Patients' preferences: what makes treatments worthwhile? In Martine J. Piccart .. [et al.] (Eds.), Breast cancer and molecular medicine, (pp. 925-944). Berlin ; New York: Springer.
  • Charles (nee Slaviero), K., Rivory, L., Stockler, M., Beale, P., Beith, J., Boyer, M., Clarke, S. (2006). Predicting the toxicity of weekly docetaxel in advanced cancer. Clinical Pharmacokinetics, 45(6), 611-622. [More Information]
  • Hauser, C., Stockler, M., Tattersall, M. (2006). Prognostic factors in patients with recently diagnosed incurable cancer: a systematic review. Supportive Care in Cancer, 14, 999-1011. [More Information]
  • Gill, P., Gebski, V., Wetzig, N., Ung, O., Campbell, I., Collins, J., Sourjina, T., Coskinas, X., Stockler, M., Simes, R. (2006). Sentinel node (SN) based management causes less arm swelling and better quality of life than routine axillary clearance (AC): 1 year outcomes of the SNAC trial. Breast Cancer Research and Treatment, 100(Supplement 1), S14-S14.
  • Cebon, J., Hargreaves, C., Stockler, M., Boyer, M., Nowak, A., Dhillon, H., Gebski, V., Dickman, B., Findlay, M., Poon, A., et al (2006). Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. British Journal of Cancer, 95(7), 853-861. [More Information]
  • Stockler, M., Heritier, S., Nowak, A., Goldstein, D., Turner, J., Jefford, M., Glasgow, A., Abdi, E., Beale, P., Carter, C. (2006). The time taken to complete quality of life questionnaires in an advanced cancer trial. Journal of Clinical Oncology, 24(18S), 491s-491s.

2005

  • Koczwara, B., Tattersall, M., Barton, M., Coventry, B., Dewar, J., Millar, J., Olver, I., Schwarz, M., Starmer, D., Turner, D., Stockler, M. (2005). Achieving equal standards in medical student education: is a national exit examination the answer? Medical Journal of Australia, 182(5), 228-230. [More Information]
  • Joshua, A., Celermajer, D., Stockler, M. (2005). Beauty is in the eye of the examiner: reaching agreement about physical signs and their value. Internal Medicine Journal, 35(3), 178-187. [More Information]
  • Pavlakis, N., Schmidt, R., Stockler, M. (2005). Bisphosphonates for breast cancer. Cochrane Database of Systematic Reviews, (3), CD003474. [More Information]
  • Duric, V., Stockler, M., Butow, P., Sharpe, L., Heritier, S., Beith, J., Boyle, F., Wilcken, N., Coates, A., Simes, R. (2005). Comparing patients' and their partners' preferences for adjuvant chemotherapy (ACT) in early breast cancer (EBC). Journal of Clinical Oncology, 23(16S), 546S-546S.
  • Haran, M., Lee, B., King, M., Marial, O., Stockler, M. (2005). Health status rated with the Medical Outcomes Study 36-Item Short-Form Health Survey after spinal cord injury. Archives of Physical Medicine and Rehabilitation, 86(12), 2290-2295. [More Information]
  • Medd, J., Stockler, M., Collins, R., Lalak, A. (2005). Measuring men's opinions of prostate needle biopsy. ANZ Journal of Surgery, 75(8), 662-664. [More Information]
  • Wetzig, N., Gill, P., Ung, O., Collins, J., Kollias, J., Gillett, D., Gebski, V., Greig, C., Ray, A., Stockler, M. (2005). Participation in the RACS sentinel node biopsy versus axillary clearance trial. ANZ Journal of Surgery, 75(3), 98-100. [More Information]
  • Duric, V., Stockler, M., Heritier, S., Boyle, F., Beith, J., Sullivan, A., Wilcken, N., Coates, A., Simes, R. (2005). Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now? Annals of Oncology, 16(11), 1786-1794. [More Information]
  • Duric, V., Fallowfield, L., Saunders, C., Houghton, J., Coates, A., Stockler, M. (2005). Patients' preferences for adjuvant endocrine therapy in early breast cancer: what makes it worthwhile? British Journal of Cancer, 93(12), 1319-1323. [More Information]
  • Stockler, M. (2005). Review: bisphosphonates are modestly better than placebo for relieving painful bone metastases. ACP Journal Club, 143(1), 13. [More Information]
  • Nowak, A., Stockler, M., Chow, P., Findlay, M. (2005). Use of Tamoxifen in Advanced-Stage Hepatocellular Carcinoma. Cancer, 103(7), 1408-1414. [More Information]
  • Clarke, S., Boyer, M., Stockler, M., Venkatawaran, R., Nordman, I., Joshua, A. (2005). Weekly docetaxel as second line treatment after mitoxantrone for androgen-independent prostate cancer (AIPC). 2005 ASCO Annual Meeting, NY, USA: American Society of Clinical Oncology.
  • Joshua, A., Nordman, I., Venkataswaran, R., Clarke, S., Stockler, M., Boyer, M. (2005). Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer. Internal Medicine Journal, 35(8), 468-472. [More Information]
  • Thewes, B., Meiser, B., Duric, V., Stockler, M., Taylor, A., Stuart-Harris, R., Links, M., Wilcken, N., McLachlan, S., Phillips, K., Boyle, F., et al (2005). What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile? Lancet Oncology, 6(8), 581-588. [More Information]

2004

  • Cox, K., O'Connell, R., Stockler, M., Boyer, M., Beale, P., Simes, R. (2004). A randomized crossover trial of giving high-dose cisplatin with or without an overnight stay in hospital: Patients' preferences, quality of life, safety and resource use. Journal of Clinical Oncology, 22(14S), 547S-547S.
  • Stockler, M., Vardy, J., Pillai, A., Warr, D. (2004). Acetaminophen (Paracetamol) Improves Pain And Well-Being In People With Advanced Cancer Already Receiving A Strong Opioid Regimen: A Randomized, Double-Blind, Placebo-Controlled Cross-Over Trial. Journal of Clinical Oncology, 22(16), 3389-3394.
  • Nowak, A., Stockler, M., Byrne, M. (2004). Assessing Quality Of Life During Chemotherapy For Pleural Mesothelioma: Feasibility, Validity, And Results Of Using The European Organization For Research And Treatment Of Cancer Core Quality Of Life Questionnaire And Lung Cancer Module. Journal of Clinical Oncology, 22(15), 3172-3180.
  • Vardy, J., Engelhardt, K., Cox, K., Jacquet, J., McDade, A., Boyer, M., Beale, P., Clarke, S., Stockler, M., Loneragan, R., Waugh, R., Clarke, S. (2004). Long-Term Outcome Of Radiological-Guided Insertion Of Implanted Central Venous Access Port Devices (Cvapd) For The Delivery Of Chemotherapy In Cancer Patients: Institutional Experience And Review Of The Literature. British Journal of Cancer, 91(6), 1045-1049.
  • Duric, V., Stockler, M., Butow, P., Sharpe, L., Beith, J., Sullivan, A., Boyle, F., Dhillon, H., Coates, A., Simes, R. (2004). Predictors of the benefits women consider necessary to make adjuvant chemotherapy (ACT) worthwhile for early breast cancer (EBC). Journal of Clinical Oncology, 22(14S), 73S-73S.
  • Joshua, A., Stockler, M., Boyer, M. (2004). Prolonged survival after the diagnosis of metastatic hepatic epitheliod haemangioendothelioma. Internal Medicine Journal, 34(1-2), 70-71.
  • Nowak, A., Wilcken, N., Stockler, M., Hamilton, A., Ghersi, D. (2004). Systematic Review Of Taxane-Containing Versus Non-Taxane-Containing Regimens For Adjuvant And Neoadjuvant Treatment Of Early Breast Cancer. Lancet Oncology, 5(6), 372-380.
  • Glare, P., Pereira, G., Kristjanson, L., Stockler, M., Tattersall, M. (2004). Systematic Review Of The Efficacy Of Antiemetics In The Treatment Of Nausea In Patients With Far-Advanced Cancer. Supportive Care in Cancer, 12(6), 432-440. [More Information]

2003

  • Pavlakis, N., Stockler, M. (2003). Bisphosphonates for breast cancer. Cochrane Database of Systematic Reviews, 11.
  • Stockler, M., Wilcken, N., Coates, A. (2003). Chemotherapy for advanced breast cancer- how long should it continue? Breast Cancer Research and Treatment, 81(Suppl 1), S49-S52.
  • Beslija, S., Bonneterre, J., Burstein, H., Gnant, M., Goodwin, P., Heinemann, V., Jassem, J., Köstler, W., Krainer, M., Menard, S., Stockler, M., et al (2003). Consensus on medical treatment of metastatic breast cancer. Breast Cancer Research and Treatment, 81(Supplement 1), S1-S7.
  • Wilcken, N., Stockler, M. (2003). Fulvestrant: spreading the word, but not too thinly. The Lancet, 11, 1254-1254.
  • Jefford, M., Stockler, M., Tattersall, M. (2003). Outcomes research: what is it and why does it matter? Internal Medicine Journal, 33(3), 110-118.
  • Eckermann, S., Martin, A., Stockler, M., Simes, R. (2003). The benefits and costs of tamoxifen for breast cancer prevention. Australian and New Zealand Journal of Public Health, 27(1), 34-40.

2002

  • Boyer, M., Stockler, M., Rosenthal, M., Eisinger, D., Goad, J., Webb, D. (2002). Adjuvant mitoxantrone chemotherapy for men at high risk of relapse following radical prostatectomy: a pilot study. UroOncology, 2(1), 15-17.
  • Pavlakis, N., Stockler, M. (2002). Bisphosphonates in breast cancer. Cochrane Database of Systematic Reviews, , 1-28.
  • Wetzig, N., Gill, P., Ung, O., Collins, J., Kollias, J., Gillette, D., Gebski, V., Greig, C., Ray, A., Stockler, M. (2002). Eligibility and Choice in the royal Australiasian College of Surgeons "SNAC Trial" of Sentinel Node Biopsy versus axillary clearance in operable breast cancer. 3rd International Sentinel Node Congress.
  • Horvath, L., McCaughan, B., Stockler, M., Boyer, M. (2002). Resection of residual pulmonary masses after chemotherapy in patients with metastatic non-seminomatous germ cell tumours. Internal Medicine Journal, 32(3), 79-83.

2001

  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, C., Liberati, A., et al (2001). Addition of drug/s to a chemotherapy regimen for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Basser, R., Henderson, I., Brunswick, C., Fossati, R., Liberati, A., et al (2001). Antitumor antibiotic containing regimins for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
  • Craig, J., Irwig, L., Stockler, M., Barratt, A., Cumming, R., Caplehorn, J. (2001). Clinical epidemiology education: to help culture change now and generate new research later. 4th International Conference on the Scientific Basis of Health Services.
  • Toner, G., Stockler, M., Boyer, M., Jones, M., Thomson, D., Harvey, V., Olver, I., Dhillon, H., McMullen, A., Gebski, V., Levi, J., Simes, R. (2001). Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. The Lancet, 357(9528), 739-745.
  • Craig, J., Irwig, L., Stockler, M. (2001). Evidence-based medicine: useful tools for decision making. Medical Journal of Australia, 174, 248-253.
  • Gooden, B., Smith, M., Tattersall, S., Stockler, M. (2001). Hospitalised patients' views on doctors and white coats. Medical Journal of Australia, 175, 219-222.
  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, R., Liberati, A., et al (2001). Larger vs smaller dose of the same drug/s regimen for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
  • Duric, V., Stockler, M. (2001). Patients' preferences for adjuvant chemotherapy in early breast cancer: a review of what makes it worthwhile? Lancet Oncology, 2(11), 691-697.
  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, R., Liberati, A., et al (2001). Platinum containing reimens for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, R., Liberati, A., et al (2001). Single agent vs combination chemotherapy for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, C., Liberati, A., et al (2001). Taxane containing regimens for metastatsic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, R., Liberati, A., et al (2001). Two drug combinations vs combinations of 3 or more cytotoxic drugs for meastatic brest cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.

2000

  • Stockler, M., Wilcken, N., Ghersi, D., Simes, R. (2000). Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treatment Reviews, 26(3), 151-168.

To update your profile click here. For support on your academic profile contact .